Modulation of cisplatin chronotoxicity related to reduced glutathione in mice

Human & Experimental Toxicology

Volumn 15, Issue 7, 1996, Pages 563-572

  Boughattas, N A ^a,b   Filipski, J ^c   Lemaigre, G ^d   Filipski, E ^a   Bouzouita, K ^b   Belhadj, O ^e  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITY OF MONASTIR   (Tunisia)

^c INSTITUT JACQUES MONOD   (France)

^d HÔPITAL ANTOINE BÉCLÈRE   (France)

^e FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

Author keywords

buthionine sulfoximine; circadian rhythm; cisplatin; reduced glutathione; toxicity

Indexed keywords

BUTHIONINE SULFOXIMINE; CISPLATIN; GLUTATHIONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; CIRCADIAN RHYTHM; COLON; CONTROLLED STUDY; DARKNESS; DRUG TOXICITY; INTRAVENOUS DRUG ADMINISTRATION; JEJUNUM; KIDNEY PARENCHYMA; LIGHT; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE LEVEL;

ANIMALIA;

EID: 0030054374     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1177/096032719601500703     Document Type: Article

References (39)

1. Wever R. The circadian system of man. Results of experiments under temporal isolation. Springer Verlag, New York, 1979.
2. Shin HS et al. An unusual coding sequence from a Drosophila clock gene is conserved in vertebrates. Nature 1985; 317: 445-448.
3. Konopka RJ Genetics of biological rhythms in drosophila. Ann Rev Genet 1987; 21: 277-286.
4. Hrushesky W., Lévi F., Halberg F., Kennedy BJ Circadian stage dependence of cis-diammine dichloroplatinum lethal toxicity in rats. Cancer Res 1982; 42: 945-949.
5. Lévi F. et al. Reduction of cis-diammine dichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. Cancer Res 1982; 42: 950-955.
6. Lévi F. et al. Lethal nephrotoxicity and hematologic toxicity of cis-diammine dichloroplatinum ameliorated by optimal circadian timing and hydration. Eur J Cancer Clin Oncol 1982; 18: 471-477.
7. Boughattas NA et al. Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice. J Pharm Exp Therap 1990; 255: 672-679.
8. Boughattas NA et al. Circadian rhythm in toxicities and tissue uptake of oxaliplatin in mice. Cancer Res 1989; 49: 3362-3368.
9. Boughattas NA et al. Circadian time dependence of murine tolerance for carboplatin. Toxicol Appl Pharmacol 1988; 96: 233-247.
10. Boughattas NA et al. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time. Biopharm Drug Disposit 1994; 15: 761-773.
11. Redmont Sms et al. Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and 06-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res 1991; 51: 2092-2097.
12. Wendling F., Moreau-Gachelin F., Tambourin P. Emergence of tumorigenic cells during the course of Friend virus leukemias. Cell Biol 1981; 78: 3614-3618.
13. Ellman JL Tissue sulphydryl groups. Arch Biochem 1959; 82: 70-77.
14. Lévi F. et al. Circadian time dependence of murine tolerance for the alkylating agent peptichemio. Eur J Cancer Clin Oncol 1987; 23: 487-497.
15. Nelson W., Tong Y., Lee JK, Halberg F. Methods for cosinor rhythmometry. Chronobiologia 1979; 6: 305-323.
16. Belanger PM Chronobiological variation in the hepatic elimination of drugs and toxic chemical agents. Ann Rev Chronopharmacol. Reinberg A, Smolensky M, Labrecque G (eds). Pergamon Press, New York, Vol. 4, pp. 1-46, 1987.
17. Belanger PM, Desgagne M., Bruguerolle B. Circadian periodicity in the glutathione concentration of rat liver. Ann Rev Chronopharmacol. Reinberg A, Smolensky M, Labrecque G (eds). Pergamon Press, New York, Vol. 4, pp. 215-218, 1988.
18. Belanger PM, Desgagne M., Bruguerolle B. Temporal variations in microsomal lipid peroxidation and in glutathione concentration of rat liver. Drug Metab Disposit 1991; 19: 241-244.
19. Lach H. et al. Cosinor analysis of diurnal changes of the reduced glutathione level in the blood, brain, liver and kidneys of mice, induced by ACTH administration. Acta Biol Hung 1986; 37: 93-100.
20. White BP, Davies MH, Schnell RC Circadian variations in hepatic glutathione content, gammaglutamylcysteine synthetase and gamma-glutamyl transferase activities in mice. Toxicol Lett 1987; 35: 217-223.
21. Jaeger RJ, Conelly R., Murphy S. Diurnal variation of hepatic glutathione concentration and its correlation with 1-1 dichloro-ethylene inhalation toxicity in rats. Res Comm Chem Path Pharmacol 1973; 6: 465-471.
22. Jaeschke H., Wendel A. Diurnal fluctuation and pharmacological alteration of mouse organ glutathione content. Biochem Pharmacol 1985; 34: 1029-1033.
23. Schnell RC et al. Factors influencing circadian rhythms in acetaminophen lethality. Pharmacology 1984; 29: 149-157.
24. Drewinko B., Brown BW, Gottlieb JA The effect of cis-diamminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implications. Cancer Res 1973; 33: 3091-3095.
25. Roberts JJ, Fravalh NA The interaction of antitumor platinum compounds with cellular DNA in cultured cells and animal tissues relationship to DNA cellular repair processes. Biochimie 1978; 60: 869-877.
26. Meyn RE, Meistrich ML, White RA Cycle-dependent anticancer drug cytotoxicity in mammalian cells synchronized by centrifugal elutriation. J Natl Cancer Inst 1980; 64: 1215-1219.
27. Edwards PG, Niasa HW Cell cycle sensitivity to cis-dichloro-bis (isopropylamine) trans-dihydroxy platinum (IV) (CHIP). Cell Tissue Kinet 1986; 19: 419-427.
28. Edwards PG Evidence that glutathione may determine the differential cell-cycle phase toxicity of a platinum (IV) antitumor agent. J Natl Cancer
29. Ohara H., Terasima T. Variations of cellular sulphydryl content during cell cycle of Hela cell and its correlation to cyclic change of X-ray sensitivity. Exptl Cell Res 1969; 58: 182-185.
30. Smaaland R. et al. Glutathione in human bone marrow and its circadian stage relation to DNA synthesis. Ann Rev Chronopharmacol. Reinberg A Smolensky M, Labrecque G (eds). Pergamon Press New York, Vol. 7, pp. 237-240, 1991.
31. Nakano S., Gemba M. Potentiation of cisplatin-induced lipid peroxidation in kidney cortical slices by glutathione depletion. Jpn J Pharmacol 1989; 50: 87-92.
32. Boor PJ Cardiac glutathione: diurnal rhythm and variation in drug-induced cardiomyopathy. Res Commun Chem Pathol Pharmacol 1979; 24: 27-36.
33. Lévi R. Chronopharmacologie de trois agents doués d'activité anticancéreuse chez le rat et la souris. Chronoefficacité et chronotolérance. Ph.D. thesis. Université Pierre et Marie Curie, Paris VI, 1982.
34. Sothern RB et al. Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment. J Natl Cancer Inst 1989; 81: 135-145.
35. Caussanel JP et al. Phase I trial of 5-day continuous infusion of oxaliplatin at circadian rhythm modulated rate compared with constant rate. J Natl Cancer Inst 1990; 82: 1046-1050.
36. Lévi F. et al. Chemotherapy of advanced ovarian cancer with 4′-O-tetra-hydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. Clin Oncol 1990; 8: 705-714.
37. Lévi F. et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatinum using an ambulatory multichannel programmable pump: high antitumor effectivenes against metastatic colorectal cancer. Cancer 1992 69: 893-900.
38. Lévi F. et al. Oxaliplatin activity against metastati colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993; 29A: 1280-1284.
39. Lévi F. et al. Chronomodulated versus fixed infusion-rate delivery of ambulatory chemotherap with oxaliplatin, fluorouracil and folinic (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. Natl Cancer Inst 1994; 86: 1608-1617.